Clinical trial Recruiting at 1 site Observational Ages 18 to 80

Evaluating single antiplatelet therapy after stent implantation for brain aneurysms

Official title: A Single-center, Prospective, Cohort Study of the Safety and Efficacy of Single Antiplatelet Therapy After Pipeline Flex with Shield Stent Implantation for Intracranial Aneurysms

Run by Xuanwu Hospital, Beijing · NCT06474884 · Data updated 2026-11-12

This study is testing whether taking one type of blood-thinning medication after getting a stent for brain aneurysms is safe and effective for patients with unruptured aneurysms.

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment165 (estimated)
SponsorXuanwu Hospital, Beijing
Academic / other
Locations1 site (Beijing)
StatusRecruiting
StartedJanuary 1, 2024
Main results expectedDecember 30, 2024
Study endsDecember 30, 2025
Registry record updatedDecember 10, 2024
Trial IDNCT06474884 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients with unruptured intracranial aneurysms who have undergone successful Pipeline Flex with Shield stent implantation.

Probably not a fit

Patients with recurrent aneurysms or those who have undergone previous interventional treatments may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the safety and efficacy of single antiplatelet therapy following the implantation of the Pipeline Flex with Shield stent in patients with unruptured intracranial aneurysms. It is a single-center, prospective cohort study that will follow participants for a period of six months post-implantation. The study includes patients who meet specific vascular conditions and have a successful stent placement, while excluding those with recurrent aneurysms or irregularly shaped aneurysms.

Why it matters

Potential benefit: If successful, this study could provide insights into safer and more effective treatment options for patients with intracranial aneurysms.

How similar studies have gone: While there may be studies on antiplatelet therapy in similar contexts, this specific approach with the Pipeline Flex with Shield stent is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients with unruptured intracranial aneurysms who received the intracranial Pipeline Flex with Shield stent.
2. Vascular conditions:

1\) There was no obvious calcification and stenosis of the parent artery. 2) The curvature of the bearing artery is minimal. 3) The parent artery diameter ≥2.5mm

3.According to the committee's assessment, only one Pipeline flex with shield is needed for aneurysm treatment.

4.Before the stent implantation procedure, standard dual antiplatelet therapy should be administered for at least 3 days.

5.Patients with an Modified Rankin Scale(mRS) score of less than 2 on the day of registration.

6.The operation was successful, and immediate postoperative angiography indicated good wall apposition.

Exclusion Criteria:

1. Patients with recurrent aneurysms after interventional treatment or surgical clipping.
2. The patient after stent placement surgery.
3. Aneurysms can have irregular shapes, such as fusiform, blister-type, or dissecting aneurysms.
4. The patient had no history of stroke or aneurysm rupture in the last 3 months.
5. Abnormal platelet function, or platelet count \< 100,000 cells/mm³.
6. Known history of allergy to clopidogrel or heparin.

Where it's running

  • Xuanwu Hospital, Capital Medical University
    Beijing, China
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.